Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma
Renáta Váraljai(Vrije Universiteit Brussel), Alexander Roesch(Essen University Hospital), Felix C. E. Vogel(German Cancer Research Center), Batool Shannan(Vrije Universiteit Brussel), Nils von Neuhoff(Leibniz University Hannover), Jérémie Nsengimana(University of Leeds), Dirk Schadendorf(National Center for Tumor Diseases), Jan‐Malte Placke(Düsseldorf University Hospital), Antje Sucker(German Cancer Research Center), Teofila Seremet(University of Lausanne), Kilian Wistuba‐Hamprecht(Vrije Universiteit Brussel), Jürgen C. Becker(Düsseldorf University Hospital), Heike Chauvistré(Essen University Hospital), Joey Mark S. Diaz(University of Leeds), Andreas Stang(Boston University), Bart Neyns(Universitair Ziekenhuis Brussel), Julia Newton‐Bishop(University of Leeds), Péter Horn, Klaus Griewank(Düsseldorf University Hospital), Benjamin Weide(University Children's Hospital Tübingen), Susanne Horn(Vrije Universiteit Brussel)
Cited by 54
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Mutations in <i>GNA11</i> in Uveal Melanoma
|New England Journal of Medicine|2010|1.5k